These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10347985)

  • 1. Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group.
    Sandström E; Wahren B
    Lancet; 1999 May; 353(9166):1735-42. PubMed ID: 10347985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trial. European Multinational IMMUNO AIDS Vaccine Study Group.
    Goebel FD; Mannhalter JW; Belshe RB; Eibl MM; Grob PJ; de Gruttola V; Griffiths PD; Erfle V; Kunschak M; Engl W
    AIDS; 1999 Aug; 13(12):1461-8. PubMed ID: 10465068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term increase of CD4+ central memory cells in HIV-1-infected individuals by therapeutic HIV-1 rgp160 immunization.
    Gudmundsdotter L; Boström AC; Burton C; Rosignoli G; Sandström E; Hejdeman B; Wahren B; Imami N; Gotch F
    Vaccine; 2008 Sep; 26(40):5107-10. PubMed ID: 18455841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of >or=500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946).
    Kundu-Raychaudhuri S; Sevin A; Kilgo P; Nokta M; Pollard RB; Merigan TC
    AIDS Res Hum Retroviruses; 2001 Oct; 17(15):1371-8. PubMed ID: 11679149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection.
    Eron JJ; Ashby MA; Giordano MF; Chernow M; Reiter WM; Deeks SG; Lavelle JP; Conant MA; Yangco BG; Pate PG; Torres RA; Mitsuyasu RT; Twaddell T
    Lancet; 1996 Dec; 348(9041):1547-51. PubMed ID: 8950881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody to human immunodeficiency virus type 1 (HIV-1) gp160 in mucosal specimens of asymptomatic HIV-1-infected volunteers parenterally immunized with an experimental recombinant HIV-1 IIIB gp160 vaccine. The National Institute of Allergy and Infectious Diseases-sponsored AIDS Vaccine Evaluation Group.
    Lambert JS; Viscidi R; Walker MC; Clayman B; Winget M; Wolff M; Schwartz DH
    Clin Diagn Lab Immunol; 1997 May; 4(3):302-8. PubMed ID: 9144368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.
    Birx DL; Loomis-Price LD; Aronson N; Brundage J; Davis C; Deyton L; Garner R; Gordin F; Henry D; Holloway W; Kerkering T; Luskin-Hawk R; McNeil J; Michael N; Foster Pierce P; Poretz D; Ratto-Kim S; Renzullo P; Ruiz N; Sitz K; Smith G; Tacket C; Thompson M; Tramont E; Yangco B; Yarrish R; Redfield RR
    J Infect Dis; 2000 Mar; 181(3):881-9. PubMed ID: 10720508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune responses to a recombinant human immunodeficiency virus type 1 (HIV-1) gpl60 vaccine among adults with advanced HIV infection. Massachusetts gp160 Working Group.
    DeMaria A; Kunches L; Mayer K; Cohen C; Epstein P; Werner B; Day J; DeCristofaro J; Landers S; Tang Y; Coady W
    J Hum Virol; 2000; 3(4):182-92. PubMed ID: 10990166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. VaxSyn Protocol Team.
    Pontesilli O; Guerra EC; Ammassari A; Tomino C; Carlesimo M; Antinori A; Tamburrini E; Prozzo A; Seeber AC; Vella S; Ortona L; Aiuti F
    AIDS; 1998 Mar; 12(5):473-80. PubMed ID: 9543445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.
    Pollard RB; Rockstroh JK; Pantaleo G; Asmuth DM; Peters B; Lazzarin A; Garcia F; Ellefsen K; Podzamczer D; van Lunzen J; Arastéh K; Schürmann D; Clotet B; Hardy WD; Mitsuyasu R; Moyle G; Plettenberg A; Fisher M; Fätkenheuer G; Fischl M; Taiwo B; Baksaas I; Jolliffe D; Persson S; Jelmert O; Hovden AO; Sommerfelt MA; Wendel-Hansen V; Sørensen B
    Lancet Infect Dis; 2014 Apr; 14(4):291-300. PubMed ID: 24525316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of HIV recombinant envelope vaccines in HIV-infected infants and children. National Institutes of Health-sponsored Pediatric AIDS Clinical Trials Group (ACTG-218).
    Lambert JS; McNamara J; Katz SL; Fenton T; Kang M; VanCott TC; Livingston R; Hawkins E; Moye J; Borkowsky W; Johnson D; Yogev R; Duliege AM; Francis D; Gershon A; Wara D; Martin N; Levin M; McSherry G; Smith G
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(5):451-61. PubMed ID: 9859958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
    Gorse GJ; Corey L; Patel GB; Mandava M; Hsieh RH; Matthews TJ; Walker MC; McElrath MJ; Berman PW; Eibl MM; Belshe RB
    AIDS Res Hum Retroviruses; 1999 Jan; 15(2):115-32. PubMed ID: 10029244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-dependent cellular cytotoxicity in HIV type 1-infected patients receiving VaxSyn, a recombinant gp160 envelope vaccine.
    Cox JH; Garner RP; Redfield RR; Aronson NE; Davis C; Ruiz N; Birx DL
    AIDS Res Hum Retroviruses; 1999 Jun; 15(9):847-54. PubMed ID: 10381173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137).
    Valentine FT; Kundu S; Haslett PA; Katzenstein D; Beckett L; Spino C; Borucki M; Vasquez M; Smith G; Korvick J; Kagan J; Merigan TC
    J Infect Dis; 1996 Jun; 173(6):1336-46. PubMed ID: 8648205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active immunization of patients with HIV infection: a study of the effect of VaxSyn, a recombinant HIV envelope subunit vaccine, on progression of immunodeficiency.
    Tsoukas CM; Raboud J; Bernard NF; Montaner JS; Gill MJ; Rachlis A; Fong IW; Schlech W; Djurdjev O; Freedman J; Thomas R; Lafrenière R; Wainberg MA; Cassol S; O'Shaughnessy M; Todd J; Volvovitz F; Smith GE
    AIDS Res Hum Retroviruses; 1998 Apr; 14(6):483-90. PubMed ID: 9566550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular immune responses in asymptomatic human immunodeficiency virus type 1 (HIV-1) infection and effects of vaccination with recombinant envelope glycoprotein of HIV-1.
    Gorse GJ; Simionescu RE; Patel GB
    Clin Vaccine Immunol; 2006 Jan; 13(1):26-32. PubMed ID: 16425996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeated immunization with recombinant gp160 human immunodeficiency virus (HIV) envelope protein in early HIV-1 infection: evaluation of the T cell proliferative response.
    Ratto-Kim S; Sitz KV; Garner RP; Kim JH; Davis C; Aronson N; Ruiz N; Tencer K; Redfield RR; Birx DL
    J Infect Dis; 1999 Feb; 179(2):337-44. PubMed ID: 9878016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed-type hypersensitivity to recombinant HIV envelope glycoprotein (rgp160) after immunization with homologous antigen.
    Katzenstein DA; Kundu S; Spritzler J; Smoller BR; Haszlett P; Valentine F; Merigan TC
    J Acquir Immune Defic Syndr; 1999 Dec; 22(4):341-7. PubMed ID: 10634195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postvaccination C-Reactive Protein and C5/gp41
    Huang Y; Zhang L; Jolliffe D; Sanchez B; Stjernholm G; Jelmert Ø; Ökvist M; Sommerfelt MA
    AIDS Res Hum Retroviruses; 2018 Mar; 34(3):307-313. PubMed ID: 29297230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expansion of restricted cellular immune responses to HIV-1 envelope by vaccination: IL-7 and IL-12 differentially augment cellular proliferative responses to HIV-1.
    Kim JH; Loveland JE; Sitz KV; Ratto Kim S; Mclinden RJ; Tencer K; Davis K; Burke DS; Boswell RN; Redfield RR; Birx DL
    Clin Exp Immunol; 1997 May; 108(2):243-50. PubMed ID: 9158092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.